Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma

A Phase I Open Label Study of HG146 Alone /in Combination with PD-(L)1 Inhibitor Administered with and Without Anticancer Agents in Participants with Advanced Solid Tumors or Lymphoma

This is a Phase I, open-label, repeat-dose, non-randomized, multicenter study to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of HG146 administered orally (PO) alone (Part 1) or co-administered (Part 2) with PD-（L）1 inhibitor in subjects with refractory/relapsed solid tumors or Lymphoma. Part 1 consists of a dose escalation phae,Part2 consists of a dose escalation phase and a cohort expansion phase. In Part 1, escalating doses of HG146 will be evaluated as guided by the "3+3" approach. In Part 2A, escalating doses of HG146 in combination with PD-(L)1 inhibitor will be evaluated as guided by the "3+3" approach. In Part 2B, subjects will receive a single dose level of HG146 as identified based on data from Part 2, in combination with PD-(L)1 inhibitor . A total of approximately 96 subjects will be enrolled in this study, approximately 36 for dose escalation cohorts, and approximately 60 in the expansion cohorts.

Study Overview

• Status: Recruiting
• Conditions: Lymphoma; Solid Tumor
• Intervention / Treatment: Drug: HG146; Drug: PD-(L)1 antibody

• Study Type: Interventional
• Enrollment (Estimated): 96
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Jie Shen; Phone Number: 8211 8628-85197385; Email: jie.shen@hitgen.com

Study Locations

• China
  • Beijing, China
    • Recruiting
    • National Cancer Center/Cancer Hospital
    • Contact: Yu mei Che; Phone Number: 8211 8628-85197385; Email: ym.che@hitgen.com
    • Contact: Yuankai Shi; Email: syuankaipumc@126.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Key Inclusion Criteria:

1 Subject must be >=18 years of age at the time of signing the informed consent.

2- Ia/Ib dose escalation phase（Part1 and Part 2A）：Subjects with advanced/Metastatic solid tumors or Lymphoma, who have progressed on, be intolerant of, or ineligible for, all available therapies for which clinical benefit has been established.

• Ib dose expansion phase（Part 2）:

  1. Cohort 1,Subjects with advanced/Metastatic solid tumors or Lymphoma, who have progressed on, be intolerant of, or ineligible for, all available therapies for which clinical benefit has been established, have not been treated with PD-(L)1 antibody； 2）Cohort 2,Subjects with advanced/Metastatic solid tumors or Lymphoma, who have progressed on, be intolerant of, or ineligible for, all available therapies for which clinical benefit has been established, have progressed on PD-(L)1 antibody； 3 Measurable disease per RECIST version 1.1 or Lugano 2014（If applicable）. 4 Has Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1. 5 Has adequate organ function. 6 Signed informed consent form (ICF) and able to comply with study requirements.

Key Exclusion Criteria:

1. Received prior therapies targeting HDAC.
2. Symptomatic central nervous system (CNS) metastases that have required steroids within 4 weeks prior to first dose of study treatment.
3. History of intolerant of anti-PD-(L)1 toxicity（Ib）.
4. A condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of enrollment.
5. Major surgery or major injury <=28 days before the first dose of study treatment,or anticipated major surgery during the study.
6. Received other anticaner therapies within 4 weeks prior to first dose of study treatment or 5 half life period of anticancer drug .
7. Active infection requiring systemic treatment.
8. Prior allogeneic bone marrow transplantation or other solid organ transplantation ( Ib)
9. Active autoimmune disease or disease of impaired immune system(Ib).
10. History of Adrenal insufficiency.(Ib)
11. History orConcurrent condition of other malignant tumors.
12. Recent (within the past 6 months) history of Unstable or serious diseases, such as pancreatitis, severe angina, prolonged QT interval, congestive heart failure, myocardial infarction, pulmonary hypertension, stroke, and severe seizures, etc.
13. History of severe lung disease.
14. Any illness or medical conditions that are unstable or could jeopardize the safety of the patient and his/her compliance in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Part 1:HG146 Monotherapy, Dose-escalation Cohort; Subjects will receive HG146 PO at every two days intervals (qod) for 14 consecutive days,7 days off, 21 days/ cycle. Escalating doses of HG146 will be evaluated using 3+3 approach.	Drug: HG146; HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
Experimental: Part 2A:HG146 + PD-(L)1 antibody, Dose escalation Cohort; Subjects will receive HG146 PO at every two days intervals (qod) for 14 consecutive days,7 days off, along with PD-(L)1 antibody IV once every 3 weeks (Q3W),21 days/ cycle. Escalating doses of HG146 in combination with PD-(L)1 antibody will be evaluated.	Drug: HG146; HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.; Drug: PD-(L)1 antibody; PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.
Experimental: Part 2B-1：HG146 combination Expansion Cohort 1; Subjects who have not been treated with PD-(L)1 antibody，will receive HG146 po for 14 consecutive days,7 days off, in combination with PD-(L)1 antibody IV Q3W.	Drug: HG146; HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.; Drug: PD-(L)1 antibody; PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.
Experimental: Part 2B-2：HG146 combination Expansion Cohort 2; Subjects who have progressed on PD-(L)1 antibody, will receive HG146 po for 14 consecutive days,7 days off, in combination with PD-(L)1 antibody IV Q3W.	Drug: HG146; HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.; Drug: PD-(L)1 antibody; PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Part 1:Number of participants experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v.5.0)	Up to 26 Days in Cycle 0 and Cycle 1
Part 1:Number of participants experiencing Serious Adverse Events (SAEs) and Adverse Events (AE)	Up to 2 years
Part1:Maximum tolerated dose or Recommended Phase Ib dose (RP2D) of HG146	Up to 2 years
Part 2A:Number of participants experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v.5.0)	Up to 21 Days in Cycle 1
Part 2A:Number of participants experiencing Serious Adverse Events (SAEs) and Adverse Events (AE)	Up to 2 years
Part 2A:Maximum tolerated dose or Recommended Phase Ib dose (RP2D) of HG146 in combination with PD-(L)1 antibody	Up to 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
OS		Up to 2 years
Part 1:Area under the concentration versus time curve (AUC) of HG146	Plasma concentration of HG146 will be measured following single dose and multiple dose administration	At the end of Cycle 0 Day 5 (Cycle 0 is 5 days);At the end of Cycle 1 Day15 (Except for cycle 0, each cycle is 21 days)
Part 1:Peak plasma concentration (Cmax) of HG146	Plasma concentration of HG146 will be measured following single dose and multiple dose administration	At the end of Cycle 0 Day 5 (Cycle 0 is 5 days);At the end of Cycle 1 Day15 (Except for cycle 0, each cycle is 21 days)
Part 1:Time of Cmax (Tmax) of HG146	Plasma concentration of HG146 will be measured following single dose and multiple dose administration	At the end of Cycle 0 Day 5 (Cycle 0 is 5 days);At the end of Cycle 1 Day15(Except for cycle 0, each cycle is 21 days)
Part 1:Apparent terminal half-life (T1/2) of HG146	Plasma concentration of HG146 will be measured following single dose and multiple dose administration	At the end of Cycle 0 Day 5 (Cycle 0 is 5 days);At the end of Cycle 1 Day15 (Except for cycle 0, each cycle is 21 days)
Part1: objective response rate (ORR)	ORR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)	Up to 2 years
Part1: Best overall response (BOR)	BOR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)	Up to 2 years
Part1: Duration of response (DOR)	DOR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)	Up to 2 years
Part 1:Time-to-response (TTR)	TTR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)	Up to 2 years
Part 1:Progression-Free Survival (PFS)	PFS will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)	Up to 2 years
Part 2:Area under the concentration versus time curve (AUC) of HG146	Plasma concentration of HG146 will be measured following multiple dose administration in combination with PD-(L)1 antibody	At the end of Cycle 1 Day 15 (each cycle is 21 days)
Part 2:maximum observed plasma concentration (Cmax) of HG146	Plasma concentration of HG146 will be measured following multiple dose administration in combination with PD-(L)1 antibody	At the end of Cycle 1 Day 15 (each cycle is 21 days)
Part 2:time of maximum observed plasma concentration (Tmax) of HG146	Plasma concentration of HG146 will be measured following multiple dose administration in combination with PD-(L)1 antibody	At the end of Cycle 1 Day 15 (each cycle is 21 days)
Part 2:apparent terminal half-life (T1/2) of HG146	Plasma concentration of HG146 will be measured following multiple dose administration in combination with PD-(L)1 antibody	At the end of Cycle 1 Day 15 (each cycle is 21 days)
Part2: objective response rate (ORR)	ORR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)	Up to 2 years
Part2: Best overall response (BOR)	BOR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)	Up to 2 years
Part2: Duration of response (DOR)	DOR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)	Up to 2 years
Part 2:Time-to-response (TTR)	TTR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)	Up to 2 years
Part 2:Progression-Free Survival (PFS)	PFS will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)	Up to 2 years

Collaborators and Investigators

• Sponsor: HitGen Inc.
• Investigators: Principal Investigator: Yuankai Shi, National Cancer Center/Cancer Hospital

Study record dates

Study Major Dates

• Study Start (Actual): July 28, 2023
• Primary Completion (Estimated): December 1, 2024
• Study Completion (Estimated): December 1, 2024

Study Registration Dates

• First Submitted: July 12, 2021
• First Submitted That Met QC Criteria: July 23, 2021
• First Posted (Actual): July 26, 2021

Study Record Updates

• Last Update Posted (Actual): October 10, 2024
• Last Update Submitted That Met QC Criteria: October 8, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma; Physiological Effects of Drugs; Immunologic Factors; Antibodies
• Other Study ID Numbers: HG146CN102

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No